A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-Risk/Recurrent Poor Prognosis Head and Neck Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2013
At a glance
- Drugs Sunitinib (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Adverse reactions
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Jan 2013 Planned end date changed from 1 Jul 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.